Pharmacogenomic Analysis of Cytogenetic Response in Chronic Myeloid Leukemia Patients Treated with Imatinib

Clinical Cancer Research

Volumn 10, Issue 1 I, 2004, Pages 155-165

  McLean, Lee Anne ^a,c   Gathmann, Insa ^a   Capdeville, Renaud ^a   Polymeropoulos, Mihael H ^a,b   Dressman, Marlene ^a,b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Vanda Pharmaceuticals Inc   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTEGRIN; HYDROXYUREA; IMATINIB; OLIGONUCLEOTIDE;

ADULT; APOPTOSIS; ARTICLE; BONE MARROW; CELL ADHESION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UNINDEXED SEQUENCE;

ANTINEOPLASTIC AGENTS; BONE MARROW; CYTOGENETIC ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RNA, NEOPLASM; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 1642453732     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0784-3     Document Type: Article

References (64)

1. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., and Kantarjian, H. M. The biology of chronic myeloid leukemia. N. Engl. J. Med., 341: 164-172, 1999.
2. Chopra, R., Pu, Q. Q., and Elefanty, A. G. Biology of BCR-ABL. Blood Rev., 13: 211-229, 1999.
3. Deininger, M. W., Goldman, J. M., and Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood, 96: 3343-3356, 2000.
4. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., Druker, B., Goldman, J., O'Brien, S. G., Russell, N., Fischer, T., Ottmann, O., Cony-Makhoul, P., Facon, T., Stone, R., Miller, C., Tallman, M., Brown, R., Schuster, M., Loughran, T., Gratwohl, A., Mandelli, F., Saglio, G., Lazzarino, M., Russo, D., Baccarani, M., and Morra, E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 346: 645-652, 2002.
5. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
6. Druker, B. J., Sawyers, C. L., Capdeville, R., Ford, J. M., Baccarani, M., and Goldman, J. M. Chronic myelogenous leukemia. Hematology (Am. Soc. Hematol. Educ. Program), 87-112, 2001.
7. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J. L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J. M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A. E., Capdeville, R., and Druker, B. J. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med., 348: 994-1004, 2003.
8. Ramaswamy, S., and Golub, T. R. DNA microarrays in clinical oncology. J. Clin. Oncol., 20: 1932-1941, 2002.
9. Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfield, C. D., and Lander, E. S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (Wash. DC), 286: 531-537, 1999.
10. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Thorsen, T., Quist, H., Matese, J. C., Brown, P. O., Botstein, D., Eystein, L. P., and Borresen-Dale, A. L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA, 98: 10869-10874, 2001.
11. Dressman, M. A., Walz, T. M., Lavedan, C., Barnes, L., Buchholtz, S., Kwon, I., Ellis, M. J., and Polymeropoulos, M. H. Genes that co-cluster with estrogen receptor α in microarray analysis of breast biopsies. Pharmacogenomics J., 1: 135-141, 2001.
12. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R., and Friend, S. H. Gene expression profiling predicts clinical outcome of breast cancer. Nature (Lond.), 415: 530-536, 2002.
13. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., and Chinnaiyan, A. M. Delineation of prognostic biomarkers in prostate cancer. Nature (Lond.), 412: 822-826, 2001.
14. Hofmann, W. K., de Vos, S., Elashoff, D., Gschaidmeier, H., Hoelzer, D., Koeffier, H. P., and Ottmann, O. G. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor ST1571 and gene-expression profiles: a gene-expression study. Lancet, 359: 481-486, 2002.
15. + chronic myeloid leukemia (CML): results of a randomized phase III study versus interferon α + cytarabine (IFN+AraC). Blood, 100: 2a, 2002.
16. Sokal, J. E., Baccarani, M., Russo, D., and Tura, S. Staging and prognosis in chronic myelogenous leukemia. Semin. Hematol., 25: 49-61, 1988.
17. Kabarowski, J. H., and Witte, O. N. Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia. Stem Cells, 18: 399-408, 2000.
18. Salgia, R., Sattler, M., Pisick, E., Li, J. L., and Griffin, J. D., p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the proto-oncogene product p120c-Cbl. Exp. Hematol., 24: 310-313, 1996.
19. Bonacchi, A., Romagnani, P., Romanelli, R. G., Efsen, E., Annunziato, F., Lasagni, L., Francalanci, M., Serio, M., Laffi, G., Pinzani, M., Gentilini, P., and Marra, F. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J. Biol. Chem., 276: 9945-9954, 2001.
20. Cai, S., Pestic-Dragovich, L., O'Donnell, M. E., Wang, N., Ingber, D., Elson, E., and De Lanerolle, P. Regulation of cytoskeletal mechanics and cell growth by myosin light chain phosphorylation. Am. J. Physiol., 275: C1349-CI356, 1998.
21. Sells, M. A., Knaus, U. G., Bagrodia, S., Ambrose, D. M., Bokoch, G. M., and Chernoff, J. Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Curr. Biol., 7: 202-210, 1997.
22. Sanders, L. C., Matsumura, F., Bokoch, G. M., and De Lanerolle, P. Inhibition of myosin light chain kinase by p21-activated kinase. Science (Wash. DC), 283: 2083-2085, 1999.
23. Papakonstanti, E. A., and Stournaras, C. Association of PI-3 kinase with PAK1 leads to actin phosphorylation and cytoskeletal reorganization. Mol. Biol. Cell, 13: 2946-2962, 2002.
24. Fukata, M., Nakagawa, M., Kuroda, S., and Kaibuchi, K. Cell adhesion and Rho small GTPases. J. Cell. Sci., 112 (Pt. 24): 4491-4500, 1999.
25. Hughes, C. A., and Bennett, V. Adducin: a physical model with implications for function in assembly of spectrin-actin complexes. J. Biol. Chem., 270: 18990-18996, 1995.
26. Jinno, S., Yageta, M., Nagata, A., and Okayama, H. Cdc6 requires anchorage for its expression. Oncogene, 21: 1777-1784, 2002.
27. Mazaki, Y., Hashimoto, S., Okawa, K., Tsubouchi, A., Nakamura, K., Yagi, R., Yano, H., Kondo, A., Iwamatsu, A., Mizoguchi, A., and Sabe, H. An ADP-ribosylation factor GTPase-activating protein Git2-short/KIAA0148 is involved in subcellular localization of paxillin and actin cytoskeletal organization. Mol. Biol. Cell, 12: 645-662, 2001.
28. Boshans, R. L., Szanto, S., van Aelst, L., and D'Souza-Schorey, C. ADP-ribosylation factor 6 regulates actin cytoskeleton remodeling in coordination with Rac1 and RhoA. Mol. Cell. Biol., 20: 3685-3694, 2000.
29. Suzuki, S. T. Protocadherins and diversity of the cadherin superfamily. J. Cell. Sci., 109 (Pt. 11): 2609-2611, 1996.
30. Cuppen, E., van Ham, M., Wansink, D. G., de Leeuw, A., Wieringa, B., and Hendriks, W. The zyxin-related protein TRIP6 interacts with PDZ motifs in the adaptor protein RIL and the protein tyrosine phosphatase PTP-BL. Eur. J. Cell Biol., 79: 283-293, 2000.
31. Jain, S. K., Langdon, W. Y., and Varticovski, L. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase. Oncogene, 14: 2217-2228, 1997.
32. Thien, C. B., and Langdon, W. Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell. Biol., 2: 294-307, 2001.
33. Lupher, M. L. J., Andoniou, C. E., Bonita, D., Miyake, S., and Band, H. The c-Cbl oncoprotein. Int. J. Biochem. Cell. Biol., 30: 439-444, 1998.
34. Yan, Z., DeGregori, J., Shohet, R., Leone, G., Stillman, B., Nevins, J. R., and Williams, R. S. Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc. Natl. Acad. Sci. USA, 95: 3603-3608, 1998.
35. Shaywitz, A. J., and Greenberg, M. E. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem., 68: 821-861, 1999.
36. Guo, G. G., Patel, K., Kumar, V., Shah, M., Fried, V. A., Etlinger, J. D., and Sehgal, P. B. Association of the chaperone glucose-regulated protein 58 (GRP58/ER-60/ERp57) with Stat3 in cytosol and plasma membrane complexes. J. Interferon Cytokine Res., 22: 555-563, 2002.
37. Henderson, Y. C., Guo, X. Y., Greenberger, J., and Deisseroth, A. B. Potential role of bcr-abl in the activation of JAK1 kinase. Clin. Cancer Res., 3: 145-149, 1997.
38. Coles, L. C., and Shaw, P. E. PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway. Oncogene, 21: 2236-2244, 2002.
39. 2-terminal kinase pathway in human neutrophils. J. Biol. Chem., 277: 40687-40696, 2002.
40. Galcheva-Gargova, Z., Gangwani, L., Konstantinov, K. N., Mikrut, M., Theroux, S. J., Enoch, T., and Davis, R. J. The cytoplasmic zinc finger protein ZPR1 accumulates in the nucleolus of proliferating cells. Mol. Biol. Cell, 9: 2963-2971, 1998.
41. Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., Wasik, M. A., Tsichlis, P. N., and Calabretta, B. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J., 16: 6151-6161, 1997.
42. Franke, T. F., Kaplan, D. R., and Cantley, L. C. PI3K: downstream AKTion blocks apoptosis. Cell, 88: 435-437, 1997.
43. Battle, T. E., and Frank, D. A. The role of STATs in apoptosis. Curr. Mol. Med., 2: 381-392, 2002.
44. Bowman, T., Garcia, R., Turkson, J., and Jove, R. STATs in oncogenesis. Oncogene, 19: 2474-2488, 2000.
45. Reuther, J. Y., Reuther, G. W., Cortez, D., Pendergast, A. M., and Baldwin, A. S. J. A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev., 12: 968-981, 1998.
46. Beg, A. A., and Baltimore, D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science (Wash. DC), 274: 782-784, 1996.
47. Sinha, S., Jancarik, J., Roginskaya, V., Rothermund, K., Boxer, L. M., and Corey, S. J. Suppression of apoptosis and granulocyte colony-stimulating factor-induced differentiation by an oncogenic form of Cbl. Exp. Hematol., 29: 746-755, 2001.
48. Mills, J. C., Stone, N. L., Erhardt, J., and Pittman, R. N. Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. J. Cell. Biol., 140: 627-636, 1998.
49. Jin, Y., Atkinson, S. J., Marrs, J. A., and Gallagher, P. J. Myosin II light chain phosphorylation regulates membrane localization and apoptotic signaling of tumor necrosis factor receptor-1. J. Biol. Chem., 276: 30342-30349, 2001.
50. Schurmann, A., Mooney, A. F., Sanders, L. C., Sells, M. A., Wang, H. G., Reed, J. C., and Bokoch, G. M. p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol. Cell. Biol., 20: 453-461, 2000.
51. Chiang, C. W., Harris, G., Ellig, C., Masters, S. C., Subramanian, R., Shenolikar, S., Wadzinski, B. E., and Yang, E. Protein phosphatase 2A activates the proapoptotic function of BAD in interleukin-3-dependent lymphoid cells by a mechanism requiring 14-3-3 dissociation. Blood, 97: 1289-1297, 2001.
52. Yoshida, K., Komatsu, K., Wang, H. G., and Kufe, D. c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damage. Mol. Cell. Biol., 22: 3292-3300, 2002.
53. Gilmore, T., Gapuzan, M. E., Kalaitzidis, D., and Starczynowski, D. Rel/NF-κB/IκB signal transduction in the generation and treatment of human cancer. Cancer Lett., 181: 1-9, 2002.
54. Chen, C., Edelstein, L. C., and Gelinas, C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell. Biol., 20: 2687-2695, 2000.
55. Matsui, H., Hikichi, Y., Tsuji, I., Yamada, T., and Shintani, Y. LIGHT, a member of the tumor necrosis factor ligand superfamily, prevents tumor necrosis factor α-mediated human primary hepatocyte apoptosis, but not Fas-mediated apoptosis. J. Biol. Chem., 277: 50054-50061, 2002.
56. Tada, K., Okazaki, T., Sakon, S., Kobarai, T., Kurosawa, K., Yamaoka, S., Hashimoto, H., Mak, T. W., Yagita, H., Okumura, K., Yeh, W. C., and Nakano, H. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-κB activation and protection from cell death. J. Biol. Chem., 276: 36530-36534, 2001.
57. Aizawa, S., Nakano, H., Ishida, T., Horie, R., Nagai, M., Ito, K., Yagita, H., Okumura, K., Inoue, J., and Watanabe, T. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF-κB activation. J. Biol. Chem., 272: 2042-2045, 1997.
58. Rooney, I. A., Butrovich, K. D., Glass, A. A., Borboroglu, S., Benedict, C. A., Whitbeck, J. C., Cohen, G. H., Eisenberg, R. J. and Ware, C. F. The lymphotoxin-β receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J. Biol. Chem., 275: 14307-14315, 2000.
59. Andoniou, C. E., Thien, C. B., and Langdon, W. Y. Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO J., 13: 4515-4523, 1994.
60. Bhat, A., Kolibaba, K., Oda, T., Ohno-Jones, S., Heaney, C., and Druker, B. J. Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells. J. Biol. Chem., 272: 16170-16175, 1997.
61. Joazeiro, C. A., Wing, S. S., Huang, H., Leverson, J. D., Hunter, T., and Liu, Y. C. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science (Wash. DC), 286: 309-312, 1999.
62. Lupher, M. L. J., Rao, N., Lill, N. L., Andoniou, C. E., Miyake, S., Clark, E. A., Druker, B., and Band, H. Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323. J. Biol. Chem., 273: 35273-35281, 1998.
63. Sattler, M., Pride, Y. B., Quinnan, L. R., Verma, S., Malouf, N. A., Husson, H., Salgia, R., Lipkowitz, S., and Gfiffin, J. D. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene, 21: 1423-1433, 2002.
64. Kaneta, Y., Kagami, Y., Katagiri, T., Tsunoda, T., Jin-nai, I., Taguchi, H., Hirai, H., Ohnishi, K., Ueda, T., Emi, N., Tomida, A., Tsuruo, T., Nakamura, Y., and Ohno, R. Prediction of sensitivity to ST1571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. Jpn. J. Cancer Res., 93: 849-856, 2002.